Blueprint Medicines (BPMC) Misses Q3 EPS by 5c
Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($0.96), $0.05 worse than the analyst estimate of ($0.91).
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($0.96), $0.05 worse than the analyst estimate of ($0.91).
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.